Role of endothelial dysfunction in coronary artery disease and implications for therapy

American Journal of Cardiology

Volumn 80, Issue 9 A, 1997, Pages

  Kinlay, Scott ^a   Ganz, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CELL ADHESION; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE ADHERENCE; PRIORITY JOURNAL; RISK FACTOR; SMOOTH MUSCLE FIBER;

EID: 0030779616     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00793-5     Document Type: Conference Paper

References (67)

1. Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Ganz P. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opinion Lipidol. 7:1996;389-397.
2. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
3. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 82:1990;II-38-II-46.
4. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques role of extracellular lipid, macrophage, and smooth muscle content . Br Heart J. 69:1993;377-381.
5. Falk E. Why do plaques rupture? Circulation. 86:(suppl III):1992;30-42.
6. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
7. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 336:1997;1276-1282.
8. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol. 76:1995;24C-33C.
9. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 86:1989;2839-2843.
10. Fuster V, Badimon JJ. Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. Eur Heart J. 16:(suppl E):1995;6-12.
11. Moreno PR, Bernardi VH, López-Cuéllar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscles cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 94:1996;3090-3097.
12. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA. 88:1991;8154-8158.
13. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 94:1994;2493-2503.
14. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 75:1994;181-189.
15. Galis ZS, Sukhova G, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA. 92:1995;402-406.
16. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography detection of matrix metalloproteinase activity in vascular tissue . FASEB J. 9:1995;974-980.
17. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, Clowes AW. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 92:1995;1393-1398.
18. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques potential role of matrix-degrading metalloproteinases and implications for plaque rupture . Circulation. 92:1995;1565-1569.
19. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 11:1991;1223-1230.
20. Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
21. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 2:1989;941-944.
22. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions a structural analysis with histopathological correlation . Circulation. 87:1993;1179-1187.
23. Luscinskas FW, Kansas GS, King H, Pizcueta P, Schleiffenbaum BE, Tedder TF, Gimbrone MA. Endothelium under flow is mediated via sequential action of L-selectin, β1-Integrins, and β2-Integrins. J Cell Biol. 125:1994;1417-1427.
24. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration the multistep paradigm . Cell. 76:1994;301-314.
25. Ley K, Tedder TF. Leukocyte interactions with vascular endothelium. New insights into selectin-mediated attachment and rolling. J Immunol. 155:1995;525-528.
26. Sluiter W, Pietersma A, Lamers JMJ, Koster JF. Leukocyte adhesion molecules on the vascular endothelium their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression . J Cardiovasc Pharmacol. 22:(suppl 4):1993;S37-S44.
27. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1 an inducible receptor for neutrophils related to complement regulatory proteins and lectins . Science. 243:1989;1160-1165.
28. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA. 84:1987;9238-9242.
29. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-γ tissue distribution, biochemistry, function of a natural adherence molecule (ICAM-1) . J Immunol. 137:1986;245-254.
30. Pober JS, Gimbrone MA Jr, Lapierre LA, Medrick DL, Fiers W, Rothlein R, Springer TA. Overlapping patterns of activation of human endothelial cells by interleukin-1, tumor necrosis factor and immune interferon. J Immunol. 137:1986;1893-1896.
31. Rice GE, Gimbrone MA Jr, Bevilacqua MP. Tumor cell-endothelial interactions. Increased adhesion of human melanoma cells to activated vascular endothelium. Am J Pathol. 133:1988;204-210.
32. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 90:1993;1138-1144.
33. Sugiyami S, Kugiyama K, Ohgushi M, Fujimoto K, Yasue H. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries role of protein kinase C . Circ Res. 74:1994;565-575.
34. Cybulski MI, Gimbrone MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251:1991;788-791.
35. Li H, Cybulski MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb. 13:1993;197-204.
36. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
37. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327:1987;524-526.
38. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 333:1988;664-666.
39. Myers PR, Guerra R, Bates JN, Harrison DG. The vasorelaxant properties of the endothelium-derived relaxing factor more closely resembles S-nitrosocysteine than nitric oxide. Nature. 345:1990;161-163.
40. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase molecular cloning and characterization of a distinct constitutive enzyme isoform . Proc Natl Acad Sci USA. 89:1992;6348-6352.
41. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 315:1986;1046-1051.
42. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest. 95:1995;1747-1755.
43. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. The coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
44. Egashira K, Inou T, Hirooka Y, Yamada A, Maruokay Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 91:1993;29-37.
45. Anderson TJ, Meredith IT, Yeung AC, Charbonneau F, Selwyn AP, Ganz P. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 93:1996;1647-1650.
46. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol. 68:1991;1425-1430.
47. Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 89:1994;2525-2532.
48. Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris reversibility by nitroglycerin . Circulation. 73:1986;865-876.
49. Gordon JB, Ganz P, Nabel EG, Zebede J, Mudge GH, Alexander RW, Selwyn AP. Atherosclerosis and endothelial function influence the coronary vasomotor response to exercise. J Clin Invest. 83:1989;1946-1952.
50. Seiler C, Hess OM, Buechi M, Suter TM, Krayenbuehl HP. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation. 88:(part 1):1993;2139-2148.
51. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO III. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation. 92:1995;320-326.
52. Kubes P, Suzuki M, Granger DN. Nitric oxide an endogenous modulator of leukocyte adhesion . Proc Natl Acad Sci USA. 88:1991;4651-4655.
53. Bassenge E. Antiplatelet effects of endothelium-derived relaxing factor and nitric oxide donors. Eur Heart J. 12:(suppl E):1991;12-15.
54. Yao S-K, Ober JC, Krishnaswami A, Ferguson JJ, Anderson V, Golino P, Buja LM, Willerson JT. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation. 86:1992;1302-1309.
55. Hogan JC, Lewis MJ, Henderson AH. In vivo EDRF activity influences platelet function. Br J Pharmacol. 94:1988;1020-1022.
56. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemia patients. Lancet. 341:1993;1496-1500.
57. Treasure CB, Klein JL, Weintraub WS, Talley D, Stillabower ME, Kosinki AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
58. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
59. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
60. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 95:1997;324-328.
61. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJGM, Lie KI, Bruschke AVG. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 94:1996;1503-1505.
62. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wum CC, Davis BR, Braunwald E. The effect of pravastatin on recurrent coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
63. Randomized trial of cholesterol lowering therapy in 4444 patients with coronary heart disease The Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
64. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Pakcard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1303-1307.
65. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 121:1994;936-941.
66. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 89:1994;2545-2551.
67. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease the TREND study (Trial on Reversing Endothelial Dysfunction) . Circulation. 94:1996;258-265.